CSBIO(300255)2025-04-21 08:50Financial Performance - The company expects a net loss attributable to shareholders of between 120 million and 180 million yuan for the year 2024, compared to a net loss of 1.24021 billion yuan in the same period last year[2]. - The net loss after deducting non-recurring gains and losses is projected to be between 160 million and 220 million yuan, compared to a loss of 1.25822 billion yuan in the previous year[2]. - The company anticipates an impact of approximately 40 million yuan from non-recurring gains and losses on net profit for the reporting period[8]. Revenue and Sales - The decline in revenue is primarily due to the impact of centralized drug procurement policies, which affected the sales of the company's main product, low molecular weight heparin calcium injection[4]. - The company has significantly reduced sales expenses compared to the previous year by enhancing the precision management of market expenses[5]. Research and Development - Research and development expenses have also decreased significantly as the company focuses on advantageous projects and has completed the large-scale investment phase for some R&D projects[6].